Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Testosurge is a proprietary, standardized nutraceutical ingredient derived from fenugreek (*Trigonella foenum-graecum*) seeds, developed by Indus Biotech (Indus Group). It is an oral dietary supplement designed to support healthy testosterone levels, particularly in individuals with low testosterone. The extract contains a specific profile of steroidal glycosides and flavonoid glycosides. Its mechanism of action involves two primary pathways: steroidal glycosides competitively bind to sex hormone-binding globulin (SHBG), which increases the concentration of free and bioavailable testosterone in the blood. Simultaneously, flavonoid glycosides enhance endogenous testosterone production by upregulating the expression of steroidogenic acute regulatory (StAR) protein within the Leydig cells of the testes. Clinical evidence indicates that a 500 mg daily dose can significantly increase total and free testosterone levels while improving body composition by reducing body fat percentage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Testosurge.